UPDATE: Credit Suisse Upgrades LHC Group to Outperform, Sees 2015 As An Inflection

In a report published Tuesday, Credit Suisse analyst Ralph Giacobbe upgraded the rating on LHC Group LHCG from Underperform to Outperform, and raised the price target from $22.00 to $32.00. In the report, Credit Suisse noted, “Upgrading LHCG to Outperform (from Underperform), raising target price to $32 (from $22). Our 1st positive recommendation in Home Health since Dec 2008. 2015 an inflection for LHCG as: 1) payment pressure subsides, 2) regulatory backdrop improves, 3) cost savings accelerate, 4) deals mature and 5) under-levered balance sheet provides optionality.” LHC Group closed on Monday at $25.38.